CP Pharmaceutical Group is a leading and innovative R&D-driven pharmaceutical company in China. It produces a variety of biopharmaceuticals and chemical drugs and showcases a strong presence in the fields of oncology, liver disease, respiratory system, and surgery/analgesia. It owns Sino Biopharm, a Hong Kong-listed company that has over 20 holding enterprises. Sino Biopharm went listed in 2000 and was later included in the MSCI China Index and a number of Hang Seng Indexes. It has been ranked among the “Top 50 Global Pharmaceutical Enterprises” by the US magazine Pharma Exec for 7 consecutive years, and named one of “Asia’s Fab 50 Companies” by Forbes Asia for 3 consecutive years.

Sino Biopharm's subsidiaries are in Beijing, Shanghai, Nanjing, Lianyungang, etc., and it has multiple pharmaceutical production bases. Since its founding, the company has consistently achieved outstanding success and steady growth. Its core subsidiaries, Chia Tai Tianqing and Beijing Tide Pharmaceutical, have consistently ranked among the“Top 100 Chinese Pharmaceutical Industry Enterprises”. Sino Biopharm will continue to deliver its mission of “Science for a Healthier World” and focus on developing innovative therapies for patients. It is committed to becoming a world-leading pharmaceutical company.